• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发性口咽鳞状细胞癌的挽救性治疗。

Salvage treatment for recurrent oropharyngeal squamous cell carcinoma.

机构信息

Clinic of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland.

出版信息

Head Neck. 2010 Aug;32(8):989-96. doi: 10.1002/hed.21273.

DOI:10.1002/hed.21273
PMID:19953618
Abstract

BACKGROUND

This study evaluates the oncological outcome of patients with recurrent oropharyngeal squamous cell carcinoma (OPSCC) after primary radiation therapy +/- chemotherapy, primary surgical therapy, and surgical therapy followed by radiation therapy +/- chemotherapy.

METHODS

A total of 156 patients (36%) of a cohort of 427 treated for OPSCC between 1990 and 2006 developed recurrent disease. Fifty-one patients (12%) qualified for salvage treatment. Study endpoints were 5-year overall survival (OS) and disease-specific survival (DSS).

RESULTS

The 5-year OS and DSS rates after salvage treatment were 29% and 40%; after initial primary radiation therapy, 25% and 40%; after initial surgery followed by radiation therapy, 40% and 40%; and after initial surgery alone, 20% and 40%.

CONCLUSIONS

Patients with an advanced OPSCC have a considerable risk for recurrence. Despite poor ultimate outcome, salvage treatment should be attempted in patients with resectable disease, good performance status, and absence of distant metastases.

摘要

背景

本研究评估了初治为放疗±化疗、手术治疗、以及术后放疗±化疗的复发性口咽鳞状细胞癌(OPSCC)患者的肿瘤学结局。

方法

1990 年至 2006 年间,427 例 OPSCC 患者中有 156 例(36%)出现疾病复发。51 例(12%)患者符合挽救性治疗条件。研究终点为 5 年总生存率(OS)和疾病特异性生存率(DSS)。

结果

挽救性治疗后 5 年 OS 和 DSS 率分别为 29%和 40%;初治放疗后分别为 25%和 40%;初治手术+放疗后分别为 40%和 40%;初治手术单独治疗后分别为 20%和 40%。

结论

OPSCC 患者有相当大的复发风险。尽管最终预后较差,但对于可切除疾病、良好的一般状态和无远处转移的患者,应尝试挽救性治疗。

相似文献

1
Salvage treatment for recurrent oropharyngeal squamous cell carcinoma.复发性口咽鳞状细胞癌的挽救性治疗。
Head Neck. 2010 Aug;32(8):989-96. doi: 10.1002/hed.21273.
2
Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma.调强放疗治疗口咽鳞状细胞癌。
Laryngoscope. 2010 Nov;120(11):2218-22. doi: 10.1002/lary.21144.
3
Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma.二次挽救性手术治疗复发性口腔及口咽癌。
Head Neck. 2010 Aug;32(8):997-1002. doi: 10.1002/hed.21298.
4
Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx.口咽鳞状细胞癌患者治疗后的结果。
Laryngoscope. 2009 Mar;119(3):534-40. doi: 10.1002/lary.20033.
5
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.根治性放疗及治疗后颈清扫术治疗晚期口咽鳞癌患者的残留淋巴结疾病:与局部区域复发、远处转移和降低生存率的关系。
Head Neck. 2013 Oct;35(10):1454-60. doi: 10.1002/hed.23173. Epub 2012 Sep 28.
6
Biological markers and prognosis in recurrent oral cancer after salvage surgery.挽救性手术后复发性口腔癌的生物标志物与预后
Arch Otolaryngol Head Neck Surg. 2008 Jul;134(7):743-9. doi: 10.1001/archotol.134.7.743.
7
Development of a new staging system for recurrent oral cavity and oropharyngeal squamous cell carcinoma.复发性口腔和口咽鳞状细胞癌新分期系统的开发
Cancer. 1999 Oct 15;86(8):1387-95.
8
Robotic-assisted surgery for primary or recurrent oropharyngeal carcinoma.机器人辅助手术治疗原发性或复发性口咽癌。
Arch Otolaryngol Head Neck Surg. 2010 Apr;136(4):380-4. doi: 10.1001/archoto.2010.40.
9
Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience.口咽、喉和下咽癌的非手术治疗:福克斯蔡斯癌症中心的经验。
Head Neck. 2011 Oct;33(10):1433-40. doi: 10.1002/hed.21615. Epub 2010 Nov 10.
10
Surgical salvage of the oropharynx after failure of organ-sparing therapy.挽救性手术治疗挽救器官保存治疗失败后的口咽。
Head Neck. 2011 Apr;33(4):516-24. doi: 10.1002/hed.21480.

引用本文的文献

1
Challenges and Complications in the Management of Advanced Oropharyngeal Carcinoma: Role of Post-Mortem Diagnosis and Future Perspectives.晚期口咽癌管理中的挑战与并发症:尸检诊断的作用及未来展望
J Clin Med. 2024 Sep 2;13(17):5198. doi: 10.3390/jcm13175198.
2
Transoral Robotic surgery - excision of Tongue base Tumour with the Entire Hyoid bone in a Salvage Setting.经口机器人手术——在挽救性手术中切除舌根肿瘤并完整切除舌骨。
Indian J Otolaryngol Head Neck Surg. 2023 Jun;75(2):1071-1075. doi: 10.1007/s12070-022-03355-z. Epub 2022 Dec 17.
3
Outcomes of Salvage Therapy for Oropharyngeal Cancer Recurrence Following Upfront Radiation Therapy and Prognostic Factors.
头颈部放疗后挽救性治疗复发性口咽癌的疗效及预后因素分析。
Cancer Res Treat. 2023 Oct;55(4):1123-1133. doi: 10.4143/crt.2022.1046. Epub 2023 May 8.
4
Functional Outcomes After Transoral Plus Lateral Pharyngotomy Approach for Advanced Oral and Oropharyngeal Tumors.经口联合外侧咽切开术治疗晚期口腔和口咽肿瘤后的功能结局
OTO Open. 2023 Feb 23;7(1):e35. doi: 10.1002/oto2.35. eCollection 2023 Jan-Mar.
5
Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review.复发性 HPV 阳性口咽鳞状细胞癌的治疗:当代综述。
Curr Oncol Rep. 2023 May;25(5):501-510. doi: 10.1007/s11912-023-01386-5. Epub 2023 Mar 7.
6
Opportunities and Limits in Salvage Surgery in Persistent or Recurrent Head and Neck Squamous Cell Carcinoma.持续性或复发性头颈部鳞状细胞癌挽救性手术的机遇与局限
Cancers (Basel). 2021 May 18;13(10):2457. doi: 10.3390/cancers13102457.
7
Predictive value of suvmax changes between two sequential post-therapeutic FDG-pet in head and neck squamous cell carcinomas.头颈部鳞状细胞癌两次连续治疗后 FDG-PET 中 SUVmax 变化的预测价值。
Sci Rep. 2020 Oct 7;10(1):16689. doi: 10.1038/s41598-020-73914-3.
8
Salvage surgery with second free flap reconstruction for recurrent oral squamous cell carcinoma.采用二次游离皮瓣重建术的挽救性手术治疗复发性口腔鳞状细胞癌。
Heliyon. 2020 Jun 11;6(6):e04014. doi: 10.1016/j.heliyon.2020.e04014. eCollection 2020 Jun.
9
Surgical Options for Locally Advanced Oropharyngeal Cancer.局部晚期口咽癌的手术选择。
Curr Treat Options Oncol. 2019 Apr 1;20(5):36. doi: 10.1007/s11864-019-0621-x.
10
Persistent Head and Neck Cancer Following First-Line Treatment.一线治疗后持续性头颈癌
Cancers (Basel). 2018 Nov 3;10(11):421. doi: 10.3390/cancers10110421.